SCI 발표논문

SCI 발표논문

← SCI 발표논문 목록

Clin Pharmacokinet. 2017;56(6):607-615.

Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis.

, , , , , , ,

제1저자 이은봉 · 교신저자 이은봉

PMID 27722854 PMC5425488 DOI 10.1007/s40262-016-0462-8 IF 4 류마티스내과
소속 (6)
  1. Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea. leb7616@snu.ac.kr.
  2. Sanofi Genzyme, 55 Corporate Drive, Bridgewater, NJ, 08807, USA.
  3. Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA.
  4. Metroplex Clinical Research Center, 8144 Walnut Hill Lane, No. 810, Dallas, 75231, TX, USA.
  5. Arensia Exploratory Medicine GmbH, Moskauer Str. 25, 40227, Düsseldorf, Germany.
  6. Altoona Center for Clinical Research, 175 Meadowbrook Lane, Duncansville, PA, 16635, USA.

Abstract

INTRODUCTION Elevated interleukin (IL)-6 occurs in patients with active rheumatoid arthritis (RA), which has been shown to lead to a decrease in cytochrome P450 (CYP) enzyme activity and alterations in drug concentrations metabolized by CYP. IL-6 signaling blockade by IL-6 receptor (IL-6R) antagonists may reverse this effect of IL-6 and restore CYP activity. This study evaluated the pharmacokinetic profile of simvastatin (a CYP3A4 substrate) before and 1 week after a single dose of sarilumab (a human monoclonal antibody [mAb] blocking the IL-6Rα) in patients with RA, to assess potential interaction.

METHODS Nineteen patients with active RA received oral simvastatin 40 mg 1 day before and 7 days after subcutaneous injection of sarilumab 200 mg. The pharmacokinetic parameters of simvastatin and its primary metabolite, β-hydroxy-simvastatin acid, were calculated using noncompartmental analysis.

RESULTS Compared with simvastatin alone, single-dose simvastatin administration 7 days after single-dose sarilumab administration in patients with RA resulted in reduced simvastatin and β-hydroxy-simvastatin acid exposure in plasma. Mean effect ratios (90 % confidence interval) for simvastatin peak plasma concentration (C max) and area under the concentration-time curve extrapolated to infinity (AUC∞) were 54.1 % (42.2-69.4 %) and 54.7 % (47.2-63.3 %), respectively. No changes occurred in time to C max or half-life for either simvastatin or β-hydroxy-simvastatin acid after sarilumab administration.

CONCLUSIONS Sarilumab treatment resulted in a reduction in exposure of simvastatin, consistent with reversal of IL-6-mediated CYP3A4 suppression in patients with active RA, as was reported for tocilizumab with simvastatin and for sirukumab with midazolam.

CLINICAL TRIAL REGISTRATION NUMBER NCT02017639.

Figures

Fig. 1
Fig. 1 Study design. PD pharmacodynamics, PK pharmacokinetics, PO oral, SC subcutaneous
Fig. 2
Fig. 2 Mean [+SD] a simvastatin and b β-hydroxy-simvastatin acid plasma concentration–time profiles after administration of simvastatin 40 mg 1 day before and 7 days after subcutaneous injection of sarilumab 200 mg (N = 19). Pharmacokinetic parameters for two patients were not calculated because of sample stability issues during bioanalysis. SD standard deviation
Fig. 3
Fig. 3 Pharmacodynamic response data corresponding to baseline, 1 week after sarilumab administration alone (day 8), and approximately 2 weeks after sarilumab administration and 1 week after simvastatin administration (day 15) for a sIL-6R, b IL-6, and c CRP. N = 19, N = 17, and N = 19 for baseline, sarilumab, and sarilumab plus simvastatin, respectively. Data are expressed as mean ± SEM. CRP C-reactive protein, IL-6 interleukin 6, SEM standard error of the mean, sIL-6R soluble IL-6 receptor

그림 출처: PubMed Central 공개 논문 (PMC5425488)

Conflict of interest statement

FUNDING: This study was sponsored by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. Andrea Eckhart, PhD, an employee of MedThink SciCom, provided editorial assistance, which was funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. CONFLICTS OF INTEREST: Eun Bong Lee has acted as a consultant to Pfizer. Nikki Daskalakis, Christine Xu, and Barry Miller are employees of Sanofi Genzyme and may hold stock and/or stock options in the company. Anne Paccaly is an employee of Regeneron Pharmaceuticals, Inc. and may hold stock and/or stock options in the company. Roy Fleischmann has received research grants from AbbVie, Amgen, Ardea, AstraZeneca, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Eli Lilly, Merck, Pfizer, Roche, Sanofi, and UCB; and has received consulting fees from AbbVie, Akros, Amgen, AstraZeneca, Bristol-Myers Squibb, Janssen, Eli Lilly, Pfizer, Roche, and UCB. Inga Bodrug was an investigator for this study. Alan Kivitz has received research grants from, and holds stock in, Sanofi and Regeneron Pharmaceuticals, Inc. ETHICAL APPROVAL: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. INFORMED CONSENT: Informed consent was obtained from all individual participants included in this study.

그 밖의 정보
출판 형태
Clinical Trial, Phase I, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
저널
Clinical pharmacokinetics · eISSN 1179-1926
MeSH
Adult · Aged · Antibodies, Monoclonal, Humanized / pharmacology · Antirheumatic Agents / pharmacology · Arthritis, Rheumatoid / blood / drug therapy / metabolism · Cytochrome P-450 CYP3A / metabolism · Drug Interactions · Female · Humans · Hydroxymethylglutaryl-CoA Reductase Inhibitors / blood / pharmacokinetics · Interleukin-6 / blood · Male · Middle Aged · Receptors, Interleukin-6 / antagonists & inhibitors / blood · Simvastatin / analogs & derivatives / blood / pharmacokinetics · Interleukin-6 Inhibitors*
Substances
Antibodies, Monoclonal, Humanized · Antirheumatic Agents · Cytochrome P-450 CYP3A · Hydroxymethylglutaryl-CoA Reductase Inhibitors · Interleukin-6 · Receptors, Interleukin-6 · Simvastatin · Interleukin-6 Inhibitors · IL6 protein, human · IL6R protein, human · beta-hydroxy simvastatin acid · sarilumab
데이터
ClinicalTrials.gov: NCT02017639
참고문헌
28편